Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma
暂无分享,去创建一个
[1] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[2] Manabu Watanabe,et al. Predicting Therapeutic Efficacy of Transarterial Chemoembolization with Drug-Eluting Beads for Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound , 2021, Diagnostics.
[3] L. Alecu,et al. Heterogeneity of antigenic constellation in human hepatocellular carcinoma. , 2021, Experimental and therapeutic medicine.
[4] A. Lyshchik,et al. Contrast-enhanced Ultrasound Identifies Patent Feeding Vessels in Transarterial Chemoembolization Patients With Residual Tumor Vascularity , 2020, Ultrasound quarterly.
[5] Wei Yang,et al. The Perfusion Features of Recurrent Hepatocellular Carcinoma After Radiofrequency Ablation Using Contrast-Enhanced Ultrasound and Pathological Stemness Evaluation: Compared to Initial Tumors , 2020, Frontiers in Oncology.
[6] Jae Young Lee,et al. Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver-Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. , 2020, Ultrasound in medicine & biology.
[7] K. Malagari,et al. Transarterial Chemoembolization of HCC with Radiopaque Microspheres: Evaluation with Computed Tomography and the Complementary Role of Contrast-Enhanced Ultrasonography , 2020, CardioVascular and Interventional Radiology.
[8] M. Moriyama,et al. Utility of Contrast‐Enhanced Ultrasound for Early Therapeutic Evaluation of Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization , 2019, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[9] A. Gasbarrini,et al. Contrast-Enhanced Ultrasound in the Short-Term Evaluation of Hepatocellular Carcinoma after Locoregional Treatment , 2020, Digestive Diseases.
[10] W. Cheng,et al. Quantitative dynamic contrast-enhanced ultrasound to predict intrahepatic recurrence of hepatocellular carcinoma after radiofrequency ablation: a cohort study , 2020, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[11] E. Jung,et al. Color coded perfusion imaging with contrast enhanced ultrasound (CEUS) for post-interventional success control following trans-arterial chemoembolization (TACE) of hepatocellular carcinoma , 2019, PloS one.
[12] Hiroki Sato,et al. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma , 2019, World journal of gastroenterology.
[13] R. Bale,et al. Stereotactic Radiofrequency Ablation of Hepatocellular Carcinoma: a Histopathological Study in Explanted Livers , 2019, Hepatology.
[14] M. Huang,et al. Contrast-Enhanced Ultrasound in Residual Tumor of Hepatocellular Carcinoma following Transarterial Chemoembolization: Is It Helpful for Tumor Response? , 2018, BioMed research international.
[15] P. Schirmacher,et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.
[16] Y. Kono,et al. Evaluation of hepatocellular carcinoma transarterial chemoembolization using quantitative analysis of 2D and 3D real-time contrast enhanced ultrasound , 2018, Biomedical physics & engineering express.
[17] M. Abecassis,et al. AASLD guidelines for the treatment of hepatocellular carcinoma , 2018, Hepatology.
[18] X. Cui,et al. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part III – Abdominal Treatment Procedures (Long Version) , 2015, Ultraschall in der Medizin.
[19] Wei Zhang,et al. Predictive value of quantitative contrast-enhanced ultrasound in hepatocellular carcinoma recurrence after ablation. , 2015, World journal of gastroenterology.
[20] Ming-de Lu,et al. Role of portal vein tumor thrombosis in quantitative perfusion analysis of contrast-enhanced ultrasound of hepatocellular carcinoma. , 2015, Ultrasound in medicine & biology.
[21] K. McGlynn,et al. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. , 2015, Clinics in liver disease.
[22] D. Merton,et al. Contrast‐Enhanced Ultrasound Evaluation of Residual Blood Flow to Hepatocellular Carcinoma After Treatment With Transarterial Chemoembolization Using Drug‐Eluting Beads , 2015, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[23] Ming-de Lu,et al. Comparison of contrast-enhanced ultrasound and contrast-enhanced computed tomography in evaluating the treatment response to transcatheter arterial chemoembolization of hepatocellular carcinoma using modified RECIST , 2015, European Radiology.
[24] Nathalie Lassau,et al. Validation of Dynamic Contrast-Enhanced Ultrasound in Predicting Outcomes of Antiangiogenic Therapy for Solid Tumors , 2014, Investigative radiology.
[25] V. Pannain,et al. Microvascular density of regenerative nodule to small hepatocellular carcinoma by automated analysis using CD105 and CD34 immunoexpression , 2014, BMC Cancer.
[26] N. Kelekis,et al. mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization. , 2013, Diagnostic and interventional radiology.
[27] A. Gasbarrini,et al. Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. , 2013, Journal of hepatology.
[28] M. Okada,et al. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma. , 2013, European journal of radiology.
[29] C. Bartolozzi,et al. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. , 2013, European journal of radiology.
[30] Nathalie Lassau,et al. Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results. , 2013, European journal of radiology.
[31] L. Bolondi,et al. Characterization of Primary and Recurrent Nodules in Liver Cirrhosis Using Contrast-Enhanced Ultrasound: Which Vascular Criteria Should Be Adopted? , 2013, Ultraschall in der Medizin.
[32] Y. Imai,et al. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast‐enhanced US , 2013, Liver international : official journal of the International Association for the Study of the Liver.
[33] Hui-Xiong Xu,et al. Role of contrast-enhanced ultrasound in follow-up assessment after ablation for hepatocellular carcinoma. , 2013, World journal of gastroenterology.
[34] S. Lazzaroni,et al. Contrast enhanced ultrasound: Should it play a role in immediate evaluation of liver tumors following thermal ablation? , 2012, European journal of radiology.
[35] C. Dietrich,et al. An EFSUMB Introduction into Dynamic Contrast-Enhanced Ultrasound (DCE-US) for Quantification of Tumour Perfusion , 2012, Ultraschall in der Medizin.
[36] J. Bruix,et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. , 2012, Journal of hepatology.
[37] K. Stamatiou,et al. Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography. , 2012, Medical ultrasonography.
[38] K. Malagari,et al. Short-term evaluation of liver tumors after transarterial chemoembolization: limitations and feasibility of contrast-enhanced ultrasonography , 2011, Abdominal Imaging.
[39] K. Malagari,et al. Unenhanced and Contrast-Enhanced Ultrasonography During Hepatic Transarterial Embolization and Chemoembolization With Drug-Eluting Beads , 2010, CardioVascular and Interventional Radiology.
[40] Riccardo Lencioni,et al. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.
[41] Sukru Mehmet Erturk,et al. Is Contrast-Enhanced US Alternative to Spiral CT in the Assessment of Treatment Outcome of Radiofrequency Ablation in Hepatocellular Carcinoma? , 2009, Ultraschall in der Medizin.
[42] Kinuyo Hatanaka,et al. Response Evaluation of Transcatheter Arterial Chemoembolization in Hepatocellular Carcinomas: The Usefulness of Sonazoid-Enhanced Harmonic Sonography , 2008, Oncology.
[43] Xiao-Ling Yu,et al. Comparison of contrast enhanced ultrasound and contrast enhanced CT or MRI in monitoring percutaneous thermal ablation procedure in patients with hepatocellular carcinoma: a multi-center study in China. , 2007, Ultrasound in medicine & biology.
[44] Linda Chami,et al. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. , 2006, AJR. American journal of roentgenology.
[45] Linda Chami,et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. , 2006, European journal of cancer.
[46] P. Burns,et al. Radiofrequency ablation of hepatocellular carcinoma: predicting success using contrast-enhanced sonography. , 2006, AJR. American journal of roentgenology.
[47] Luigi Solbiati,et al. Guidance and monitoring of radiofrequency liver tumor ablation with contrast-enhanced ultrasound. , 2004, European journal of radiology.
[48] M. Dumont,et al. European Association for the Study of the Liver , 1971 .
[49] D. Sze,et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. , 2012, Journal of vascular and interventional radiology : JVIR.
[50] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[51] Donald L. Miller,et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. , 2012, Journal of vascular and interventional radiology : JVIR.